Ieq Capital LLC Takes Position in Xeris Biopharma Holdings, Inc. $XERS

Ieq Capital LLC purchased a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the 2nd quarter, HoldingsChannel reports. The firm purchased 98,429 shares of the company’s stock, valued at approximately $780,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in XERS. Royal Bank of Canada lifted its stake in Xeris Biopharma by 1,411.2% in the first quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock valued at $1,170,000 after acquiring an additional 198,984 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Xeris Biopharma by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock worth $461,000 after purchasing an additional 3,594 shares during the last quarter. Millennium Management LLC increased its stake in shares of Xeris Biopharma by 19.0% during the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock worth $12,726,000 after purchasing an additional 369,420 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after purchasing an additional 1,199,435 shares in the last quarter. Finally, Caxton Associates LLP bought a new position in shares of Xeris Biopharma during the 1st quarter valued at $170,000. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Trading Down 0.9%

Shares of NASDAQ:XERS opened at $8.60 on Friday. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45. The stock’s 50-day moving average is $8.26 and its 200-day moving average is $6.92. The company has a market cap of $1.57 billion, a P/E ratio of -78.18 and a beta of 0.66. Xeris Biopharma Holdings, Inc. has a 52-week low of $5.25 and a 52-week high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%.The business had revenue of $92.10 million for the quarter, compared to analyst estimates of $90.12 million. Equities research analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on XERS. Barclays upped their price objective on shares of Xeris Biopharma from $9.00 to $12.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Wall Street Zen lowered Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $12.00.

Insider Buying and Selling

In other news, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total value of $97,440.00. Following the sale, the director owned 126,500 shares in the company, valued at approximately $770,385. This trade represents a 11.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Pieper sold 27,600 shares of the business’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $8.52, for a total transaction of $235,152.00. Following the transaction, the insider directly owned 1,366,053 shares in the company, valued at $11,638,771.56. This trade represents a 1.98% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 271,499 shares of company stock worth $2,038,917. 4.35% of the stock is currently owned by company insiders.

Xeris Biopharma Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.